NCT02351856View on ClinicalTrials.gov

A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 2, 2015

Primary Completion Date

December 21, 2020

Study Completion Date

December 21, 2020

Conditions
LMNA-Related Dilated Cardiomyopathy
Interventions
DRUG

ARRY-371797, p38 inhibitor, oral

multiple dose, single schedule

Trial Locations (4)

21287

Johns Hopkins Hospital, Baltimore

53713

Meriter Wisconsin Heart, Madison

80045

University of Colorado Hospital, Aurora

02115

Brigham & Women's Hospital, Boston

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02351856 - A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy | Biotech Hunter | Biotech Hunter